Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00023660
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : November 19, 2013
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Radiation Therapy Oncology Group

September 13, 2001
January 27, 2003
November 19, 2013
August 2001
January 2005   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00023660 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer
A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy in different ways and combining it with chemotherapy may kill more tumor cells. Celecoxib may slow the growth of cervical cancer by stopping blood flow to the tumor.

PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus celecoxib, fluorouracil, and cisplatin in treating patients who have locally advanced cervical cancer.


  • Determine treatment-related toxicity rates in patients with locally advanced cervical cancer treated with external beam radiotherapy and brachytherapy concurrently with celecoxib, fluorouracil, and cisplatin.
  • Determine whether this regimen increases locoregional control rates, distant control, disease-free survival, and overall survival in these patients.
  • Determine whether first-failure patterns in patients treated with this regimen are changed compared to historical controls.

OUTLINE: This is a multicenter study.

Patients undergo external beam pelvic radiotherapy once daily five days a weeks for 5 weeks beginning on day 1. Within 8 weeks, patients undergo low-dose or high-dose brachytherapy. Patients also receive concurrent chemotherapy comprising fluorouracil IV continuously over days 2-5, 23-26, and 44-47 and cisplatin IV over 4 hours on days 1, 22, and 43. Oral celecoxib is administered twice daily beginning on day 1 and continuing for 12 months.

Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 83 patients will be accrued for this study within 1.5 years.

Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Cervical Cancer
  • Drug: celecoxib
  • Drug: cisplatin
  • Drug: fluorouracil
  • Radiation: brachytherapy
  • Radiation: radiation therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
January 2005   (Final data collection date for primary outcome measure)


  • Histologically confirmed squamous, adenocarcinoma, or adenosquamous carcinoma of the cervix

    • Stage IIB-IVA OR
    • Stage IB-IIA with pelvic node metastases and/or tumor size at least 5 cm
  • No small cell, carcinoid, glassy cell, clear cell, or adenoid cystic disease
  • No metastatic disease outside of pelvis
  • No para-aortic disease



  • 18 to 85

Performance status:

  • Zubrod 0-2

Life expectancy:

  • At least 6 months


  • WBC at least 3,000/mm^3
  • Absolute granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.5 mg/dL
  • AST or ALT no greater than 2.5 times upper limit of normal (ULN)


  • Creatinine no greater than 1.5 mg/dL
  • Creatinine clearance at least 50 mL/min
  • Calcium no greater than 1.3 times ULN


  • No severe heart disease


  • Not pregnant or nursing
  • Negative pregnancy test
  • HIV negative
  • No prior allergy to sulfonamides or non-steroidal anti-inflammatory drugs (NSAIDs)
  • No prior hypersensitivity to celecoxib or any component of its formulation
  • No medical or psychiatric illness that would preclude study
  • No active gastrointestinal (GI) ulcer, GI bleeding, or inflammatory bowel disease
  • No other prior malignancy within the past 5 years except cutaneous basal cell skin cancer


Biologic therapy:

  • No recent prior celecoxib or other cyclo-oxygenase-2 inhibitor


  • No prior systemic chemotherapy

Endocrine therapy:

  • Not specified


  • No prior radiotherapy to pelvis except transvaginal radiotherapy to control bleeding


  • No prior surgery for cervical cancer except biopsy


  • No concurrent phenytoin or lithium
  • No other concurrent NSAIDs
Sexes Eligible for Study: Female
18 Years to 85 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
Study Chair: David K. Gaffney, MD, PhD University of Utah
Radiation Therapy Oncology Group
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP